AR105507A1 - LORLATINIB FREE BASE CRYSTAL FORM - Google Patents

LORLATINIB FREE BASE CRYSTAL FORM

Info

Publication number
AR105507A1
AR105507A1 ARP160102288A ARP160102288A AR105507A1 AR 105507 A1 AR105507 A1 AR 105507A1 AR P160102288 A ARP160102288 A AR P160102288A AR P160102288 A ARP160102288 A AR P160102288A AR 105507 A1 AR105507 A1 AR 105507A1
Authority
AR
Argentina
Prior art keywords
free base
crystal form
base crystal
lorlatinib free
lorlatinib
Prior art date
Application number
ARP160102288A
Other languages
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR105507A1 publication Critical patent/AR105507A1/en

Links

Abstract

Reivindicación 1: Una forma cristalina de base libre de (10R)-7-amino-12-fluoro-2,10,16-trimetil-15-oxo-10,15,16,17-tetrahidro-2H-8,4-(meteno)pirazolo[4,3-h][2,5,11]benzoxadiazaciclotetradecina-3-carbonitrilo (lorlatinib), que tiene un patrón de difracción de rayos X de polvo (PXRD) que comprende dos o más picos en valores 2q seleccionados del grupo que consta de: 9.6, 10.1, 14.3, 16.2 y 17.3 º2q ± 0.2 º2q.Claim 1: A free base crystalline form of (10R) -7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8.4- (methane) pyrazolo [4,3-h] [2,5,11] benzoxadiazacyclotetradecin-3-carbonitrile (lorlatinib), which has a powder X-ray diffraction pattern (PXRD) comprising two or more peaks at 2q values selected from the group consisting of: 9.6, 10.1, 14.3, 16.2 and 17.3 º2q ± 0.2 º2q.

ARP160102288A 2015-07-31 2016-07-27 LORLATINIB FREE BASE CRYSTAL FORM AR105507A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562199418P 2015-07-31 2015-07-31

Publications (1)

Publication Number Publication Date
AR105507A1 true AR105507A1 (en) 2017-10-11

Family

ID=60244680

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102288A AR105507A1 (en) 2015-07-31 2016-07-27 LORLATINIB FREE BASE CRYSTAL FORM

Country Status (1)

Country Link
AR (1) AR105507A1 (en)

Similar Documents

Publication Publication Date Title
PH12018500343A1 (en) Heterocyclic amides as kinase inhibitors
BR112017002594A2 (en) tank binding kinase inhibitor compounds
PH12016501813A1 (en) 1,3-benzodioxole derivative
PL3577110T3 (en) 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl substituted compounds as hiv inhibitors
ECSP20025899A (en) COMPOUNDS USEFUL TO INHIBIT CDK7
GEP20197011B (en) Heteroaryl compounds for kinase inhibition
MY192059A (en) Heterocyclic amides as kinase inhibitors
MA39749A (en) Piperidine-dione derivatives
WO2016011390A8 (en) Irak4 inhibiting agents
WO2014052563A3 (en) Novel compounds that are erk inhibitors
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
BR112016006319A2 (en) irak inhibitors and uses thereof
EA201691194A1 (en) RHC STIMULATORS
AR091959A1 (en) SYNTHETIC SUSTAINABLE AGENTS AND MONODISPERSE SUSTAINABLE AGENTS AND METHODS FOR THE ELABORATION OF THE SAME
GEP20186933B (en) Substituted dihydroisoquinoline compounds
EA201890820A1 (en) NEW PYRROLO [2,3-d] PYRIMIDINE DERIVATIVES AS DYRK1 / CLK1 DUAL INHIBITORS
EA201591805A1 (en) OXABICICLO [2.2.2] ACIDS - MODULATORS GPR120
MX2016012451A (en) 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives.
WO2014153495A9 (en) Novel stat3 inhibitors
IL271399A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
AR103444A1 (en) CRYSTAL FORM OF A BENCIMIDAZOL DERIVATIVE AND A METHOD OF PREPARATION OF THE SAME
PH12015502122A1 (en) Sovaprevir polymorphs and methods of manufacturing thereof
TW201612165A (en) Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound
MX2015013048A (en) A crystalline form of an anxiolytic compound.
MX2016016127A (en) Crystal forms.